

International Stem Cell Corporation Subsidiary Lifeline Cell Technology Enters into Agreement with University of California to Study Macular Degeneration and Retinitis Pigmentosa

Release: 3/19/2007 8:10:00 AM

OCEANSIDE, Calif.--(BUSINESS WIRE)---International Stem Cell Corporation, Inc. (OTCBB: ISCO) announced today that its wholly owned subsidiary, Lifeline Cell Technology, LLC, has entered into a research agreement with the Regents of the University of California for three studies, one of which is focused on stem cell therapy for the possible treatment of macular degeneration and retinitis pigmentosa.

International Stem Cell Corporation's focus is on the development of stem cell based treatment of diabetes, liver disease and diseases of the retina, and on providing specialized cells and media to scientists to conduct their cell based research. It maintains corporate and research facilities in Oceanside, California; production and product development in Walkersville, Maryland; and international research facilities in Moscow, Russia.

The project with the University of California is entitled "Characterization of New Human Embryonic Stem Cell Lines and the Differentiation into Retinal Progenitor Cell" and will be under the direction of Dr. Hans Keirstead of the Reeve-Irvine Research Center at the University's Irvine Campus.

The research agreement will involve three specific projects. The first two projects will study Lifeline's proprietary stem cell lines and how they compare to traditionally-derived human embryonic stem cells.

The third project involves expanding Lifeline's ongoing studies into differentiating Lifeline's proprietary stem cells into retinal cells and their testing in animal models. The goal is the clinically compliant derivation and functional characterization of high purity populations of retinal pigment epithelial cells and photoreceptors.

This project has three aims: The first aim will improve methods to change Lifeline's proprietary stem cells into retinal cells. This research will be conducted in an FDA-compliant manner under the supervision of Regulatory Quality Assurance Officers. The second aim will test whether Lifeline's proprietary stem cells, when transplanted into rodent models with retinal degeneration, will redistribute throughout the retina, integrate and continue differentiation. The third aim will assess the ability of the transplanted retinal cells to slow down or reverse the damage caused by macular degeneration and retinitis pigmentosa in the rodent models.

"This is an important step in testing the efficacy of our proprietary stem cell lines and how they compare to traditionally-derived embryonic stem cells," said Jeffrey Janus, President of International Stem Cell Corporation.

To receive public information, including press releases, conference calls, SEC filings, profiles, investor kits, News Alerts and other pertinent information please click on the following link: <http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0>.

ABOUT LIFELINE CELL TECHNOLOGY AND INTERNATIONAL STEM CELL CORPORATION:

International Stem Cell is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO is currently developing human stem cells, techniques to cause those stem cells to be "differentiated" into the specific cell types required for transplant, and manufacturing protocols to produce the cells without contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO, through its subsidiary, Lifeline Cell Technology, produces and markets a line of products for research that includes serum-free growth media and reagents essential to the process of creating and differentiating stem cells into therapeutic products needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. For more information, visit the ISCO website at: www.internationalstemcell.com.

FORWARD LOOKING STATEMENT

This news release contains forward-looking statements relating to the business of ISCO and its subsidiary. Investors are cautioned that such forward-looking statements regarding ISCO, its technology, clinical development and potential applications, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. International Stem Cell Corporation disclaims any intent or obligation to update these forward-looking statements.

Contact:

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
kaldrich@intlstemcell.com
Jeff Krstich, CEO
jkrstich@intlstemcell.com
Jeffrey Janus, President
janusj@lifelinecelltech.com
760-940-6383

or

Investor Relations:

Capital Group Communications, Inc.

Abigail Bruce/George Carpenter

abigail@capitalgc.com

george@capitalgc.com

Office: 415-332-7200

Fax: 415-332-7201

or

Media Relations:

The Orbach Company, Inc.

Nevena Orbach, 818-904-0500

nevena@orbachco.com